PLIANT THERAPEUTICS INC (PLRX) Stock Analyst Ratings
USA - NASDAQ:PLRX - US7291391057 - Common Stock
1.6 USD
+0.07 (+4.58%)
1.5218 USD
-0.08 (-4.89%)
ChartMill assigns a Buy % Consensus number of 70% to PLRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.26. This target is 104% above the current price.
PLRX was analyzed by 16 analysts. The buy percentage consensus is at 70. So analysts seem to be have mildly positive about PLRX.
In the previous month the buy percentage consensus was at a similar level.
PLRX was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-10-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2025-08-08 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-18 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-04 | Cantor Fitzgerald | Reiterate | Neutral |
| 2025-03-04 | Needham | Downgrade | Buy -> Hold |
| 2025-03-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-03-04 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-04 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-03-04 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-03 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-02-14 | Needham | Reiterate | Buy -> Buy |
| 2025-02-14 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-10 | Needham | Maintains | Buy -> Buy |
| 2025-02-10 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-02-10 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-02-10 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-02-10 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-02-10 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-02-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-08 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-08 | Needham | Reiterate | Buy -> Buy |
| 2024-08-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-07-16 | Needham | Reiterate | Buy -> Buy |
| 2024-07-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
PLIANT THERAPEUTICS INC / PLRX FAQ
What is the average price target for PLIANT THERAPEUTICS INC (PLRX) stock?
16 analysts have analysed PLRX and the average price target is 3.26 USD. This implies a price increase of 104% is expected in the next year compared to the current price of 1.6.
What is the consensus rating for PLRX stock?
The consensus rating for PLIANT THERAPEUTICS INC (PLRX) is 70 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
What is the number of analysts for PLRX stock?
The number of analysts covering PLIANT THERAPEUTICS INC (PLRX) is 16.